By combining an immune tolerance agent with shorter bioactive Reg peptides, the potential now exists to address the underlying cause of diabetes, which neither insulin nor any current diabetes therapies on the market address.
March 24, 2020
Ocean Tomo Transactions, LLC will auction a portfolio of 10 US patents covering novel therapies for the treatment of diabetes. The patents in lot 108 disclose an invention that increases pancreatic beta cells and protects them through a generalized immune tolerance agent, such as cyclosporine. Even though new therapies are available to treat type 2 patients and numerous insulin preparations are available to treat both type 1 and 2 diabetes, none address the underlying cause of diabetes: too few beta cells. The patents in auction lot 108 disclose the use and efficacy of shorter bioactive Reg peptides to transform progenitor cells within the pancreas into new islets that generate new beta cells that produce insulin.
By combining an immune tolerance agent with shorter bioactive Reg peptides, the potential now exists to address the underlying cause of diabetes, which neither insulin nor any current diabetes therapies on the market address. In the US, the number of people diagnosed with diabetes is projected to increase to nearly 42 million by 2030. Projected diabetes‐related medical costs are likewise expected to increase to $472.0 billion by 2030.
The patents in this lot were issued from 2014 to 2016. They will expire from 2032 to 2034.
You can view the patents in Ocean Tomo Bid-Ask™ Market auction lot 108 here. To request bidder credentials or for further information on this auction or other auctions on the Ocean Tomo Bid-Ask™ Market, contact Layna Guo at Layna@OTI.com or 1-312-327-8179.
About the Ocean Tomo Bid-Ask™ Market
The Ocean Tomo Bid-Ask Market is an open on-line platform to buy and sell patents. This market is an important step forward, both as a simplified solution for patent transactions as well as a source of information on patent pricing. The Ocean Tomo Bid-Ask Market uniquely combines the efficiency of an online platform with an experienced team of brokers fluent in both English and Mandarin. The market uses standard transaction documents and is open, transparent and free to view.
Share article on social media or email: